Results 41 to 50 of about 2,200 (151)

Optimizing treatment efficacy and fertility preservation in patients undergoing hematopoietic stem cell transplantation: A narrative review of ovarian shielding with total‐body irradiation or treosulfan‐based conditioning regimens

Reproductive Medicine and Biology, Volume 24, Issue 1, January/December 2025.
Abstract Background Pediatric and adolescent/young adult (AYA) patients with hematologic malignancies often require hematopoietic stem cell transplantation (HSCT) using conditioning regimens that pose high risks for gonadal toxicity. Traditional protocols, including total body irradiation (TBI) and busulfan‐based regimens, can impair fertility.
Yuji Tanaka, Tetsuro Hanada, Tsukuru Amano, Akimasa Takahashi, Mari Deguchi, Hiroyuki Yamanaka, Shunichiro Tsuji, Takashi Murakami   +7 more
wiley   +1 more source

Risk‐Stratified and Response‐Adapted Therapy for Pediatric Hodgkin Lymphoma in Argentina: The GATLA Experience

Advances in Hematology, Volume 2025, Issue 1, 2025.
Background: The international cooperation between GATLA and AHOPCA with the support of St. Jude led to the adoption of the OEPA/COPDAC as a strategy to improve outcomes in high risk (HR) patients with HL. This study also includes the ABVD regimen for intermediate risk (IR) and low risk (LR) patients. Methods: Patients were stratified by predefined risk
David Veron, Patricia Streitenberger, Mónica Matus, Pedro Negri Aranguren, Alejandra Costa, Daniela Morell, Sergio Terrasa, E. Mauricio Castellanos, Pedro de Alarcon, Eduardo Dibar, Mónica Makiya, Suraiya Saleem   +11 more
wiley   +1 more source

Clinical potential of mechlorethamine gel for the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma: a review on current efficacy and safety data

Drug Design, Development and Therapy, 2018
Kendall Liner,1 Celeste Brown,2 Laura Y McGirt3 1Division of Dermatology, Medical College of Georgia at Augusta Health, Augusta, GA, USA; 2School of Medicine, University of North Carolina at Chapel Hill, Carolinas Medical Center, Charlotte, NC, USA ...
Liner K, Brown C, McGirt LY
doaj  

The Impact of Regularly Used Treatments on Daily Life of Cutaneous T‐Cell and B‐Cell Lymphoma Patients

JEADV Clinical Practice, Volume 4, Issue 2, Page 552-555, June 2025.
Michelle Raaijmakers, Marlies Meersman, Leen Neyens, Anne‐Marie Busschots, Pascal Wolter, F. J. Sherida H. Woei‐A‐Jin   +5 more
wiley   +1 more source

Results from a Pilot Study of HyBryte™ (Topical Synthetic Hypericin) Versus Valchlor® (Mechlorethamine) in the Treatment of CTCL

Oncology and Therapy
Introduction Mycosis fungoides (MF) is the most common type of primary cutaneous T-cell lymphoma (CTCL), a malignant and chronic skin disease. Early-stage MF has a generally favorable prognosis, but effective and well-tolerated skin-directed therapies ...
Brian Poligone, Christopher Pullion, Adam Rumage, Richard Straube, Oreola Donini, Christopher J. Schaber, Elaine S. Gilmore   +6 more
doaj   +1 more source

Reduced intensity treatment in early-stage Hodgkin’s lymphoma

Blood and Lymphatic Cancer: Targets and Therapy, 2011
Prathima Prodduturi, James O ArmitageUniversity of Nebraska Medical Center, Omaha, NE, USAAbstract: Early-stage Hodgkin’s lymphoma which includes patients with Ann Arbor stages I or II, accounts for more than 50% of all cases of the illness and
Armitage JO, Prodduturi P
doaj  

Mechlorethamine gel usage in patients with mycosis fungoides in a lymphoma clinic

Indian Journal of Dermatology, 2020
Robert Duffy, Tara Jennings, Joya Sahu
doaj   +1 more source

Mechlorethamine [PDF]

, 2020
openaire   +1 more source

Evaluation and management of patients with early-stage mycosis fungoides who interrupt or discontinue topical mechlorethamine gel because of dermatitis

JAAD Case Reports, 2020
Elaine S. Gilmore, MD, PhD, Carolina V. Alexander-Savino, BS, Catherine G. Chung, MD, Brian Poligone, MD, PhD   +3 more
doaj   +1 more source

Mechlorethamine Hydrochloride Gel [PDF]

, 2020
openaire   +1 more source